Literature DB >> 158982

Immune complex injury of the lung.

P A Ward.   

Abstract

Abundant evidence currently exists to suggest that immune complexes play an important role in inflammatory diseases of the lung. Clinically, idiopathic pulmonary fibrosis, eosinophilic granuloma of lung, and systemic lupus erythematosus have been shown to be associated with the presence of immune complexes both in lung and in the serum. Experimentally, there is compelling evidence that acute lung injury can be triggered by the deposition of complexes in vascular walls or by the presence of performed immune complexes instilled into the airways. The observed reactions are, as expected, complement- and neutrophil-dependent. The morphologic changes in lung caused by products of complement activation (C5a and related peptides) depend on whether complement activation occurs within the vasculature or within the airways. Airway activation is associated with intraalveolar accumulations of neutrophils, while intravascular activation leads to intracapillary sequestration of neutrophils. The chronic formation of immune complexes within the vasculature (in the model of "chronic serum sickness") leads to an interstitial fibrotic reaction and a thickening of basement membranes. Recent studies of intravascularly infused preformed immune complexes indicate a proclivity for certain types of complexes to localize within lung. These "lung-seeking" complexes differ from non-lung-seeking complexes only in the ratio of antigen to antibody. Complement does not seem to alter the tendancy for certain complexes to localize within lung. These studies emphasize the potential importance of immune complexes in lung injury and point out the variety of mechanisms involved in both the localization process and the injury process.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 158982      PMCID: PMC2042385     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  17 in total

1.  Pathogenetic studies in idiopathic pulmonary fibrosis. Control of neutrophil migration by immune complexes.

Authors:  J Gadek; G Hunninghake; R Zimmerman; J Kelman; J Fulmer; R G Crystal
Journal:  Chest       Date:  1979-02       Impact factor: 9.410

2.  Diffuse pulmonary interstitial disease; an immunohistologic study.

Authors:  H Eisenberg; D H Simmons; E V Barnett
Journal:  Chest       Date:  1979-02       Impact factor: 9.410

3.  The composition of pulmonary immune deposits in systemic lupus erythematosus.

Authors:  J W Eagen; J L Roberts; M M Schwartz; E J Lewis
Journal:  Clin Immunol Immunopathol       Date:  1979-02

4.  Acute inflammatory pulmonary reactions induced by chemotactic factors.

Authors:  U Desai; D L Kreutzer; H Showell; C V Arroyave; P A Ward
Journal:  Am J Pathol       Date:  1979-07       Impact factor: 4.307

Review 5.  Immunopathology of allergic lung disease.

Authors:  J Pepys
Journal:  Clin Allergy       Date:  1973-03

6.  Antibodies against pigeon serum proteins in pigeon breeders.

Authors:  J N Fink; J J Barboriak; A J Sosman; R J Bukosky; J A Arkins
Journal:  J Lab Clin Med       Date:  1968-01

7.  Suppression of immune complex-induced inflammation by the chemotactic factor inactivator.

Authors:  K J Johnson; T P Anderson; P A Ward
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

8.  Circulating immune complexes in the idiopathic interstitial pneumonias.

Authors:  R B Dreisin; M I Schwarz; A N Theofilopoulos; R E Stanford
Journal:  N Engl J Med       Date:  1978-02-16       Impact factor: 91.245

9.  Acute immunologic pulmonary alveolitis.

Authors:  K J Johnson; P A Ward
Journal:  J Clin Invest       Date:  1974-08       Impact factor: 14.808

10.  Experimental immune complex disease of the lung. The pathogenesis of a laboratory model resembling certain human interstitial lung diseases.

Authors:  J R Brentjens; D W O'Connell; I B Pawlowski; K C Hsu; G A Andres
Journal:  J Exp Med       Date:  1974-07-01       Impact factor: 14.307

View more
  16 in total

Review 1.  Polyclonal activators in pulmonary immune disease.

Authors:  W F Willoughby; J B Willoughby; G F Gerberick
Journal:  Clin Rev Allergy       Date:  1985-05

Review 2.  Stevens-Johnson syndrome: a review of the literature.

Authors:  V J Stitt
Journal:  J Natl Med Assoc       Date:  1988-01       Impact factor: 1.798

3.  Immunoglobulin classes in local immune complexes recovered by bronchoalveolar lavage in collagen vascular diseases.

Authors:  H M Jansen; A J Schutte; M van der Giessen; T H The
Journal:  Lung       Date:  1984       Impact factor: 2.584

4.  Leukocytes in chemotactic-fragment-induced lung inflammation. Vascular emigration and alveolar surface migration.

Authors:  J O Shaw
Journal:  Am J Pathol       Date:  1980-11       Impact factor: 4.307

Review 5.  Protein-based therapies for acute lung injury: targeting neutrophil extracellular traps.

Authors:  Markus Bosmann; Peter A Ward
Journal:  Expert Opin Ther Targets       Date:  2014-03-26       Impact factor: 6.902

Review 6.  Structure and function of the anaphylatoxins.

Authors:  T E Hugli
Journal:  Springer Semin Immunopathol       Date:  1984

7.  Mechanisms of neutrophil accumulation in the lungs of patients with idiopathic pulmonary fibrosis.

Authors:  G W Hunninghake; J E Gadek; T J Lawley; R G Crystal
Journal:  J Clin Invest       Date:  1981-07       Impact factor: 14.808

8.  Trimellitic anhydride-induced allergic response in the lung: role of the complement system in cellular changes.

Authors:  D G Fraser; J F Regal; M L Arndt
Journal:  J Pharmacol Exp Ther       Date:  1995-05       Impact factor: 4.030

9.  Hyperacute pulmonary vasculitis in rabbits receiving prolonged infusions of activated complement. A possible model for triggering events in adult respiratory distress syndrome.

Authors:  T K Bowers; A L Ozolins; N B Ratliff; H S Jacob; D E Hammerschmidt
Journal:  Inflammation       Date:  1983-03       Impact factor: 4.092

10.  Association of FcγRIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression.

Authors:  Stylianos Bournazos; Jacob Grinfeld; Karen M Alexander; John T Murchison; William A Wallace; Pauline McFarlane; Nikhil Hirani; A John Simpson; Ian Dransfield; Simon P Hart
Journal:  BMC Pulm Med       Date:  2010-10-07       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.